stockrow
Monday 9 November 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024.
- Revenue
- −43.9%
- EPS
- +11.3%
- Free cash flow
- −7.05%
Quarter to September 2026, against a year earlier
4.89
0.34
+7.47%
Follow TRDA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
67.66 | 66.31 | 92.01 | 16.73 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.98) | (9.57) | (12.66) | (13.21) | |
P/B ratio |
1.36 | 1.33 | 1.95 | 1.39 | |
Price to Tangible BV |
1.36 | 1.33 | 1.95 | 1.39 | |
EV/Sales |
19.13 | 18.73 | 47.60 | 5.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.56) | (0.65) | (2.07) | (1.00) | |
EV/FCF |
(0.56) | (0.65) | (2.07) | (1.00) | |
Quick Ratio |
7.49 | 10.47 | 13.32 | 12.17 | |
Current Ratio |
7.85 | 10.89 | 13.90 | 12.53 | |
Net Debt/EBITDA |
0.00 | 5.00 | 6.06 | 7.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.06 | |
Operating CF/Net income |
0.75 | 0.76 | 1.05 | 0.82 | |
Capex/Depreciation |
0.00 | (0.03) | (0.17) | 0.82 | |
Research and Development Expense of Revenue |
3,576.69% | 3,938.64% | 3,777.60% | 2,614.09% | |
Selling, General and Administrative Expense of Revenue |
1,129.83% | 1,168.37% | 1,157.03% | 735.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
527.96% | 573.50% | 542.17% | 335.49% | |
Graham Net Nets |
0.50 | 0.54 | 0.38 | 0.55 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(60.47%) | (53.80%) | (31.62%) | (33.66%) | |
Free Cash Flow Yield |
(50.67%) | (43.23%) | (24.93%) | (30.46%) | |
Revenue per Share |
0.02 | 0.02 | 0.02 | 0.03 | |
Operating CF per Share |
(0.71) | (0.77) | (1.00) | (0.78) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Free Cash Flow per Share |
(0.71) | (0.77) | (1.00) | (0.77) | |
Cash per Share |
4.55 | 5.28 | 6.09 | 7.16 | |
Shareholders Equity per Share |
4.68 | 5.53 | 6.47 | 7.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.68 | 5.53 | 6.47 | 7.40 | |
Free Cash Flow |
(30.12) | (32.47) | (41.74) | (32.00) | |
Working Capital |
177.09 | 211.33 | 247.68 | 281.80 | |
Capital Expenditures |
(0.16) | (0.01) | (0.04) | 0.21 | |
Net Current Asset Value |
134.40 | 167.24 | 202.21 | 235.01 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.18 | 0.01 | 0.05 | (0.16) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.02 | 1.00 | 1.42 | 2.43 | |
Average Payables |
4.02 | 2.80 | 2.56 | 3.27 | |
Average Assets |
339.89 | 373.83 | 411.00 | 451.85 | |
Average Common Equity |
269.52 | 306.46 | 344.06 | 367.41 |
Columns are period end dates · fundamentals updated 5 Nov 2026